

Aerocrine

Aerocrine Announces Change in Date of Publication of Third-quarter 2014 Interim Report

October 21, 2014

Solna (Sweden) – October 21, 2014 – Aerocrine AB (OMX Nordic Exchange: AERO), the innovator of NIOX® brand medical devices announces today that the previously disclosed publication date of November 6, 2014 for the company's Third-quarter Interim Report for 2014 has been moved to November 27 at 8.00 AM.

The new date is caused by a change of the Board meeting date preceding the publication.

For more information please contact any of the following individuals:

Scott Myers, Chief Executive Officer, Aerocrine AB, +46 768 788 379, +1 970 368 0336

Marshall Woodworth, Chief Financial Officer, Aerocrine AB, +46 709 695 219, +1 919 749 8748

Mats Carlson, VP Global Business Operations, Aerocrine AB, +46 705 34 89 89

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO® (EU). Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007. For more information, please visit www.aerocrine.com and www.niox.com.

Aerocrine is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 a.m. on October 21, 2014